Welcome to the website of the Dömling – Drug Design – Group from the University of Groningen. We are situated within the Faculty of Pharmacy.
Our team focusses on issues in computational chemistry and drug discovery. Particularly interesting topics for us are :
- The study of novel mdm2/mdmx inhibitors
- Drug discovery projects on various targets
- Method development for new MCR scaffolds
- High throughput methods development for drug discovery purpose
On these few pages you can browse through recent publications of the group or get to know more about current group members.
If you want to get in contact with us, feel free to send an email to A.S.S.Domling@rug.nl
Alexander Dömling studied chemistry & biology at the Technical University Munich. After performing his PhD under the supervision of Ivar Ugi he spent his postdoctoral year at the Scripps Research Institute in the group of Barry Sharpless. He is founder of several biotech companies, including Morphochem and R&D Biopharmaceuticals. In 2004 we performed his habilitation in chemistry at the Technical University of Munich. Since 2006 he is professor at the University of Pittsburgh in the Department of Pharmacy and Chemistry and most recently Chair of Drug Design at the University of Groningen. He is author of more than 100 papers, reviews and book contributions.